Immunogenic cell death (ICD) refers to an immunologically distinct process of regulated cell
death that activates, rather than suppresses, innate and adaptive immune responses. Such …

HCC, the most prevalent form of primary liver cancer, presents a substantial global health
challenge due to its high mortality and limited therapeutic options. This review delves into …

Nanovaccine-based immunotherapy has been considered as a major pillar to stimulate the
host immune system to recognize and eradicate tumor cells as well as establish a long-term …

Plasma, the fourth and most pervasive state of matter in the visible universe, is a fascinating
medium that is connected to the beginning of our universe itself. Man-made plasmas are at …

Whole tumor cell-based vaccines include all potential antigen-rich cell lysates to target a
specific type of tumor without the need to find the best antigen candidate in protein-or …

Concern of toxic compounds and their, potentially more harmful degradation products,
present in aquatic environment alarmed scientific community and research on the …

Gas plasma technology generates reactive oxygen and nitrogen species (ROS/RNS),
inducing lethal oxidative damage in tumor cells. The transfer of gas plasma–derived …

The anti-cancer properties of plasma-treated solutions (PTS) and their interaction with drugs
are one of the most popular topics in modern plasma medicine. Our research involved …

Immunogenic cell death (ICD) has emerged as a key component of therapy-induced anti-
tumor immunity. Over the past few years, ICD was found to play a pivotal role in a wide …

Strategies to improve activity and selectivity are major goals in oncological drug
development. Medical gas plasma therapy has been subject to intense research in …